Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

Immunosuppressive therapy Immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response. This prevents your immune system from attacking your bone marrow, allowing bone marrow stem cells to grow, which raises blood counts. For older patients with acquired aplastic anemia, immunosuppressive drug therapy is the… is one therapy option for treatment of patients with lower-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at… . However, the use of several different immunosuppressive regimens, the lack of high-quality studies, and the absence of validated predictive biomarkers pose important challenges. We conducted a systematic review and meta-analysis according to the Meta-Analysis of Observational Studies in Epidemiology Epidemiology: The study of patterns and causes of disease in groups of people. Epidemiology researchers study how many people have a disease, how many new cases are diagnosed each year, where patients are located, and environmental or other factors that influence disease. (MOOSE) guidelines and searched MEDLINE via PubMed, Ovid EMBASE, COCHRANE registry of clinical trials clinical trials: Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study. Understanding Clinical Trials Clinical… (CENTRAL), and the Web of Science without language restriction from inception through September 2018 as well as relevant conference proceedings and abstracts. for prospective cohort studies or clinical trials investigating immunosuppressive therapy in myelodysplastic syndromes. Fixed and Random-effects models were used to pool response rates. We identified nine prospective cohort studies and 14 clinical trials with a total 570 patients. The overall response rate was 43% (95% confidence interval [CI] 34.2%-52.3%) including a complete remission rate of 12.5% (95% CI 9.3%-16.6%) and red blood cell transfusion red blood cell transfusion: A procedure in which packed red blood cells are given to a person through an intravenous (IV) line into the bloodstream. Transfused red blood cells increase the blood count and help improve symptoms of anemia. Before transfused blood is given, donated blood is typed and crossmatched to the… independence rate of 30.6% (95% CI 23.2%-39.2%). The most commonly used forms of immunosuppressive therapy were anti-thymocyte globulin alone or in combination with cyclosporin A with a trend towards higher response rates with combination therapy. Progression rate to acute myeloid leukemia acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone marrow and become to numerous. This slows production of red blood cells and platelets. Some cases of MDS become… was 8.6% per patient year (95% CI 3.3%-13.9%). Overall survival and adverse events were only inconsistently reported. We were unable to validate any biomarkers predictive of a therapeutic response to immunosuppressive therapy. Immunosuppressive therapy for treatment of lower-risk myelodysplastic syndrome patients can be successful to alleviate transfusion burden and associated sequelae.